Breadcrumb Trail Links
WorldPublished Jul 16, 2023 • 2 minute read
A clinical trial published in the journal Nature Medicine, by Lawson Health Research Institute, the Centre hospitalier de l’Université de Montréal and the Jewish General Hospital has found fecal microbiota transplants from healthy donors can improve response to immunotherapy in patients with melanoma.
Article Content
Poop transplants may benefit melanoma treatment.
Advertisement
This advertisement has not loaded yet, but your article continues below.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Unlimited online access to articles from across Canada with one account.
- Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on.
- Enjoy insights and behind-the-scenes analysis from our award-winning journalists.
- Support local journalists and the next generation of journalists.
- Daily puzzles including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Unlimited online access to articles from across Canada with one account.
- Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on.
- Enjoy insights and behind-the-scenes analysis from our award-winning journalists.
- Support local journalists and the next generation of journalists.
- Daily puzzles including the New York Times Crossword.
REGISTER TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
Article Content
A clinical trial published in the journal Nature Medicine, by Lawson Health Research Institute, the Centre hospitalier de l’Université de Montréal and the Jewish General Hospital has found fecal microbiota transplants from healthy donors can improve response to immunotherapy in patients with melanoma.
Article Content
Immunotherapy drugs stimulate a person’s immune system to kill cancer but the drugs are reportedly only effective in 40% to 50% of patients. “In this study, we aimed to improve melanoma patients’ response to immunotherapy by improving the health of their microbiome through fecal transplants,” says Dr. John Lenehan, Medical Oncologist at London Health Sciences Centre’s London Regional Cancer Program.
From our newsroom to your inbox at noon, the latest headlines, stories, opinion and photos from the Toronto Sun. By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails or any newsletter. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300
Thanks for signing up! A welcome email is on its way. If you don’t see it, please check your junk folder. The next issue of Your Midday Sun will soon be in your inbox. We encountered an issue signing you up. Please try again
Article Content
Advertisement
This advertisement has not loaded yet, but your article continues below.
Article Content
A fecal transplant collects stool from a healthy donor and transplanting it to the patient. The procedure transplants the donor’s microbiome so that healthy bacteria will grow in the patient’s gut.
RECOMMENDED VIDEO
We apologize, but this video has failed to load. Play Video
“The connection between the microbiome, the immune system and cancer treatment is a growing field in science,” explains Dr. Saman Maleki, Scientist at Lawson and LHSC’s LRCP, Assistant Professor in Schulich Medicine’s Departments of Oncology. “This study aimed to harness microbes to improve outcomes for patients with melanoma.”
The first phase of the trial included 20 melanoma patients. Patients were given 40 fecal transplant capsules orally one week before they started immunotherapy treatment.
Article Content
Advertisement
This advertisement has not loaded yet, but your article continues below.
“We have reached a plateau in treating melanoma with immunotherapy, but the microbiome has the potential to be a paradigm shift,” says Dr. Bertrand Routy, Oncologist and Director of CHUM’s Microbiome Center. “This study puts Canada at the forefront of microbiome research by showing we can safely improve patients’ response to immunotherapy through fecal transplants.”
“These exciting results add to a rapidly growing list of publications suggesting that targeting the microbiome may provide a major advance in the use of immunotherapy for our patients with cancer,” adds Dr. Wilson H. Miller Jr. of the JGH and Professor in the Departments of Medicine and Oncology at McGill University.
Previous studies looking at patients receiving immunotherapy who do not respond have found many had an unhealthy microbiome, said Dr. Lenehan. “There’s a portion of people who don’t respond or the treatment just doesn’t work,” says Dr. Lenehan. “The hope with the fecal transplant is to make more people respond to treatment.” These results had lead researchers to of the role to look at the microbiome in regulating how the body responds to disease and how the drugs themselves interact with the microbiome.
RECOMMENDED VIDEO
We apologize, but this video has failed to load. Play Video
Article content
Share this article in your social network
Comments
Postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. Comments may take up to an hour for moderation before appearing on the site. We ask you to keep your comments relevant and respectful. We have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. Visit our Community Guidelines for more information and details on how to adjust your email settings.
Join the Conversation
Article Content
Advertisement
This advertisement has not loaded yet, but your article continues below.